Gamma Amino Butyric Acid (GABA) is the body’s most common neurotransmitter. In the Central Nervous System (CNS), it is second only to Glutamate. The two neurotransmitters combined make up 90% of all CNS Neurotransmitters. In the peripheral nervous system there are GABA receptors on the axons of nerves. GABA is a mostly inhibitory neurotransmitter, although it can also be excitatory when it turns off other GABA receptors that are inhibiting excitatory synapses.
In addition to its profound role as a neurotransmitter, GABA is also the body’s main built-in anti-inflammatory. It acts as a wall against inflammation and allows the neuroimmune system to continue functioning. It also allows inflammatory tissue-based dendritic cells and cytokines to respond to breaches in the body’s natural barrier to infection and trauma without establishing chronic inflammation. The barrier that GABA provides during inflammation can be overwhelmed and broken down, allowing the body to mount a proper inflammatory response, address the problem and re-establish homeostasis. In chronic inflammatory states, the GABA barrier is also overwhelmed, but local and brain-based events prevent return to a normal non-inflammatory condition.
NeuroplastixTM is pioneering research in novel uses of GABA in the treatment of pain. We have a patent pending on the use of GABA to treat pain and have focused on multiple routes of administration, including topical, intradermal, transdermal, intranasal, transbuccal, transvaginal, transrectal and parenteral delivery systems.
We have conducted extensive clinical case studies and have gathered data for a retrospective study of patients using GABA to control their pain over time. Future research plans are directed at randomized controlled trials to study the use of GABA to control pain using functional imaging, NMR and standardized pain scales.